We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Oncologic Drugs Committee Sends Sintilimab Back to the Starting Line
FDA Oncologic Drugs Committee Sends Sintilimab Back to the Starting Line
Members of FDA’s Oncologic Drugs Advisory Committee voted 14-1 yesterday to require a U.S. study for sintilimab, Lilly’s investigational lung cancer drug that — so far — only has Chinese trial data.